{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Self-contained study:', 'Study with objectives not linked to the data of another', 'study.', 'Site Monitor:', 'An individual assigned by the sponsor who is responsible', 'for assuring the proper conduct of epidemiological studies', 'at one or more investigational sites.', 'Study population:', 'Sample of population of interest.', 'Subject:', 'Term used throughout the protocol to denote an', 'individual who has been contacted in order to participate', 'or participates in the epidemiological study or a person', 'about whom some medical information has been recorded', 'in a database.', 'Subject number:', 'A unique number identifying a subject, assigned to each', 'subject consenting to participate in the study.', '19-OCT-2018', '25', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'TRADEMARKS', 'The following trademarks are used in the present protocol.', 'Trademarks of the GSK group of', 'Generic description', 'companies', 'COPD Assessment test (CAT)', 'Questionnaire to measure the impact of', 'COPD on wellbeing and daily life', 'EXACT-PRO', 'Exacerbations of Chronic Pulmonary', 'Disease Tool - Patient Reported Outcome', 'SGRQ-C', \"St. George's Respiratory Questionnaire for\", 'COPD patients', '19-OCT-2018', '26', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '1.', 'INTRODUCTION', '1.1.', 'Background', 'Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable', 'disease characterised by persistent airflow obstruction which is not fully reversible and', 'which is usually progressive in the long term. The classification of COPD severity is', \"done based on the patient's spirometric classification according to [GOLD, 2013]. The\", 'airflow limitation in COPD patients can be classified into GOLD grades as shown in', 'Table 1 [GOLD, 2013]. In this study, additional parameters are going to be collected in', 'order to allow for a combined assessment that could be used for future evaluation, as', 'detailed in Figure 1 [GOLD,', '2017].', 'Table 1', 'Classification of severity of airflow limitation in COPD (based on', 'post-bronchodilator FEV1)', 'GOLD grade', 'In patients with FEV1/ FVC < 0.70:', 'GOLD 1: Mild', 'FEV1 80% predicted', 'GOLD 2: Moderate', '50% FEV1 < 80% predicted', 'GOLD 3: Severe', '30% FEV1 < 50% predicted', 'GOLD 4: Very Severe', 'FEV1 < 30% predicted', 'GOLD = Global Initiative for Chronic Obstructive Lung Disease; FEV1 = forced expiratory volume in 1 second;', 'FVC = forced vital capacity', 'Figure 1', 'The refined ABCD assessment tool', 'Spirometrically', 'Assessment of', 'Assessment of', 'confirmed', 'symptoms/risk of', 'airflow limitation', 'diagnosis', 'exacerbations', 'Exacerbation', 'history', 'FEV,', '2', '(% predicted)', 'or', 'Post-bronchodilator', 'GOLD 1', '80', '1 leading', 'c', 'D', 'FEV,/FVC < 0.7', 'to hospital', 'GOLD 2', '50-79', 'admission', 'GOLD 3', '30-49', '0 or 1', 'GOLD 4', '< 30', '(not leading', 'to hospital', 'A', 'B', 'admission)', 'mMRC 0-1', 'mMRC 2', 'CAT < 10', 'CAT 10', 'Symptoms', 'GOLD = Global Initiative for Chronic Obstructive Lung Disease; CAT = COPD assessment test; FEV1 = forced', 'expiratory volume in 1 second; FVC = forced vital capacity; mMRC = Modified British Medical Research Council', 'Questionnaire', '19-OCT-2018', '27', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}